RT Journal Article
T1 Mesenchymal Stem Cell-Based Therapies in the Post-Acute Neurological COVID Syndrome: Current Landscape and Opportunities
A1 León Moreno, Lilia Carolina
A1 Reza Zaldívar, Edwin Estefan
A1 Hernández Sapiéns, Mercedes Azucena
A1 Villafaña Estarrón, Erika
A1 García Martín, Marina
A1 Ojeda Hernández, Doddy Denise
A1 Matías-Guiu, Jordi A.
A1 Gómez Pinedo, Ulises
A1 Matías-Guiu Guía, Jorge
A1 Canales Aguirre, Alejandro Arturo
AB One of the main concerns related to SARS-CoV-2 infection is the symptoms that could be developed by survivors, known as long COVID, a syndrome characterized by persistent symptoms beyond the acute phase of the infection. This syndrome has emerged as a complex and debilitating condition with a diverse range of manifestations affecting multiple organ systems. It is increasingly recognized for affecting the Central Nervous System, in which one of the most prevalent manifestations is cognitive impairment. The search for effective therapeutic interventions has led to growing interest in Mesenchymal Stem Cell (MSC)-based therapies due to their immunomodulatory, anti-inflammatory, and tissue regenerative properties. This review provides a comprehensive analysis of the current understanding and potential applications of MSC-based interventions in the context of post-acute neurological COVID-19 syndrome, exploring the underlying mechanisms by which MSCs exert their effects on neuroinflammation, neuroprotection, and neural tissue repair. Moreover, we discuss the challenges and considerations specific to employing MSC-based therapies, including optimal delivery methods, and functional treatment enhancements.
PB MDPI
YR 2023
FD 2023-12-20
LK https://hdl.handle.net/20.500.14352/104964
UL https://hdl.handle.net/20.500.14352/104964
LA eng
NO León-Moreno LC, Reza-Zaldívar EE, Hernández-Sapiéns MA, Villafaña-Estarrón E, García-Martin M, Ojeda-Hernández DD, et al. Mesenchymal Stem Cell-Based Therapies in the Post-Acute Neurological COVID Syndrome: Current Landscape and Opportunities. Biomolecules 2023;14:8. https://doi.org/10.3390/biom14010008.
NO 2023 Descuento MDPI
NO Fondo de Desarrollo Científico de Jalisco
DS Docta Complutense
RD 7 abr 2025